EMEA-001261-PIP01-11-M05

Key facts

Invented name
Halaven
Active substance
Eribulin
Therapeutic area
Oncology
Decision number
P/0264/2018
PIP number
EMEA-001261-PIP01-11-M05
Pharmaceutical form(s)
Solution for injection
Condition(s) / indication(s)
Treatment of soft tissue sarcoma
Route(s) of administration
Intravenous use
Contact for public enquiries
Eisai Europe Ltd

Tel. +44 (0)20 8600 1400
E-mail: EUMedInfo@eisai.net

Decision type
PM: decision on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating